Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 330 participants.

Also called NCT06274801

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 330 participants (planned count) (from the registry)
Sponsor
Gossamer Bio USA, Inc. (from the registry)
Registry
  • NCT NCT06274801
  • EudraCT 2023-506334-75
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, Colombia, Czechia, Denmark, France, Germany, Greece, Ireland, Israel, Italy, Japan, Latvia, Lithuania, Mexico, Netherlands, Poland, Portugal, Romania, Saudi Arabia, Serbia, Singapore, South Korea, Spain, United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06274801. Allocation not applicable; no masking; primary purpose treatment. Start 2024-09-03 (actual); primary completion 2026-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
Condition
Pulmonary Arterial Hypertension
Intervention (Drug)
Seralutinib
Intervention (Device)
Gereic Dry Powder Inhaler
Lead sponsor
Gossamer Bio USA, Inc. (class: industry)

Record details

Record id
cardio:ct-nct06274801
Content hash
729f9508db702b3b4f81c7b00afd9ef63b8f294a24bfbb641c24a62cebd28743